Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation at a tertiary care hospital in Thailand

被引:0
|
作者
Pongsathabordee, Chayanat [1 ]
Saringkarn, Piyachat [1 ]
Ratanapornsompong, Kanjana [2 ]
Rungruang, Ratiya [2 ]
Srithonrat, Saranporn [1 ]
Tangkaotong, Pimlada [1 ]
Sena, Salintip [1 ]
Paiboonvong, Taniya [1 ]
机构
[1] Rangsit Univ, Coll Pharm, Dept Pharm Practice, Pathum Thani, Thailand
[2] Rajavithi Hosp, Pharm Dept, Bangkok, Thailand
来源
EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY | 2024年 / 16卷
关键词
Direct oral anticoagulants; Atrial fibrillation; Inappropriate dosing; Inpatients; EAST-ASIAN PATIENTS; STROKE PREVENTION; WARFARIN;
D O I
10.1016/j.rcsop.2024.100507
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Appropriate dosing of direct oral anticoagulants (DOACs) has been associated with clinical efficacy and safety. Several studies have shown that DOAC dosing are often inconsistent with guideline recommendations. Little is known about this issue in Thailand. This study aimed to evaluate the appropriateness of DOAC dosing in Thai hospitalized patients with atrial fibrillation (AF). Method: This was a retrospective descriptive study conducted on hospitalized patients at Rajavithi Hospital, a tertiary care hospital in Thailand. Inpatients diagnosed with AF and treated with DOACs between February 2021 and February 2023 were enrolled in the study. The appropriate dosing of DOACs was assessed according to the recommendation of the 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (EHRA). Descriptive statistics were used to analyze the data; median (interquartile range) for continuous variables, and numbers and percentages for categorical variables. Results: A total of 120 patients with AF were evaluated for dosing. The patients received rivaroxaban in 47 cases (39.2 %), apixaban in 32 cases (26.7 %), edoxaban in 31 cases (25.8 %), and dabigatran in 10 cases (8.3 %). Most of the patients were elderly, with a median age of 77.5 (68-84) years. Females were predominant (57.5 %). Our findings indicate that the prevalence of appropriate dosing of DOACs was 63.3 %. However, approximately onethird of patients received inappropriate dosing, with 24 (20.0 %) being overdosed, and 20 (16.7 %) being underdosed. The highest overdosing and underdosing rates were seen in dabigatran (90.0 %) and apixaban (21.9 %), respectively. Conclusion: Inappropriate dosing of DOACs according to the 2021 EHRA recommendations was high in 36.7 %, with overdosing mostly occurring in 20.0 %. The high number of inappropriate dosing highlights the need for implementation of optimal strategies to select the appropriate dose of DOACs in Thai hospitalized patients with AF.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients
    Bruria Hirsh Raccah
    Amihai Rottenstreich
    Netanel Zacks
    Ilan Matok
    Haim D. Danenberg
    Arthur Pollak
    Yosef Kalish
    Journal of Thrombosis and Thrombolysis, 2019, 47 : 550 - 557
  • [2] Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients
    Raccah, Bruria Hirsh
    Rottenstreich, Amihai
    Zacks, Netanel
    Matok, Ilan
    Danenberg, Haim D.
    Pollak, Arthur
    Kalish, Yosef
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (04) : 550 - 557
  • [3] Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration
    Leef, George C.
    Perino, Alexander C.
    Askari, Mariam
    Fan, Jun
    Ho, P. Michael
    Olivier, Christoph B.
    Longo, Lisa
    Mahaffey, Kenneth W.
    Turakhia, Mintu P.
    JOURNAL OF PHARMACY PRACTICE, 2020, 33 (05) : 647 - 653
  • [4] Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation according to the drug labelling and the EHRA Practical Guide
    Capiau, Andreas
    De Backer, Tine
    Grymonprez, Maxim
    Lahousse, Lies
    Van Tongelen, Inge
    Mehuys, Els
    Boussery, Koen
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 328 : 97 - 103
  • [5] Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation
    Li, Ray J.
    Caughey, Gillian E.
    Shakib, Sepehr
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2022, 53 (02) : 425 - 435
  • [6] Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation
    Ray J. Li
    Gillian E. Caughey
    Sepehr Shakib
    Journal of Thrombosis and Thrombolysis, 2022, 53 : 425 - 435
  • [7] Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation
    Gustafson, Whitney L.
    Saunders, John
    Vazquez, Sara R.
    Jones, Aubrey E.
    Witt, Daniel M.
    PHARMACY PRACTICE-GRANADA, 2019, 17 (04):
  • [8] Appropriateness of rivaroxaban and apixaban dosing in hospitalized patients with a newly diagnosed nonvalvular atrial fibrillation at a single tertiary hospital
    Alshibani, Mohannad
    MEDICINE, 2023, 102 (36) : E35058
  • [9] Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment
    Emmeline Tran
    Ashley Duckett
    Sarah Fisher
    Nicole Bohm
    Journal of Thrombosis and Thrombolysis, 2017, 43 : 505 - 513
  • [10] Evaluation of appropriateness of direct oral anticoagulant dosing for discharge prescriptions
    Lemens, Laura M.
    Reaves, Anne B.
    Shoop, David
    Yates, Mary E. D.
    PHARMACOTHERAPY, 2017, 37 (12): : E134 - E134